India's Biotech Industry is Poised for Exponential Growth - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

India's Biotech Industry is Poised for Exponential Growth
India has the potential to become the new star of the biotechnology industry.

Pharmaceutical Technology
Volume 35, Issue 5, pp. 106

Alan Eisenberg
India is home to a robust and growing biotechnology industry because of the country's increasing premium on innovation. Maintaining and sustaining this sector, however, requires active support from government, policymakers, academia, the financial community, and others.

Biotechnology promises solutions to many of the global challenges faced by the world, and industry leaders in India recognize the myriad benefits of further developing a robust biotechnology sector within the country. Policies to encourage biotechnology investment and development will produce a significant return on investment by creating high-skill, high-wage jobs and bringing innovations to market.

Last Fall, the Biotechnology Industry Organization (BIO)and the Association of Biotechnology Led Enterprises (ABLE) hosted the inaugural BIO India International Partnering Conference in Hyderabad, to bring together biotechnology and pharmaceutical companies from North America, Europe, and Asia to explore business opportunities within India's emerging biotechnology sector. Leading companies and industry experts from India and around the world attended the conference as did many investment industries.

There is significant global competition engaging the biotech sector globally and it was clear at the conference that many multinational biotechnology and pharmaceutical firms have set their sights on India. They are eagerly entering into resaerch and development partnerships as well as licensing and distribution agreements with Indian companies.

But questions remain. Will India, for example, establish the regulatory system, public policies, and incentives it needs to encourage and support innovation?

Discussions at the 2010 BIO India meeting highlighted the need for a concerted effort to develop a comprehensive regulatory framework for the approval of biologics in India, including the approval of biosimilars. For example, the Indian government must set approval criteria for biologics and biosimilars that protect patient safety and preserve incentives to innovate. Well-crafted pathways for the approval of these drugs will lower costs by increasing competition and promote further biomedical research and development. BIO has created a list of principles on biosimilars which is available online (

BIO recognizes the efforts of the Indian government to streamline the various authorities impacting the nation's biotechnology sector and we applaud the open channel of communication between the Department of Biotechnology and the Drugs Controller General of India. These efforts, in conjunction with the Indian government's willingness to hear from various stakeholders, will be useful in shaping India's regulatory framework which, in turn, will generate investment interest in biotechnology. The Indian government also is working on economic programs to bolster its established biotech clusters, and the National Institute of Public Finance is drafting a plan to establish a venture capital-type fund to finance drug-discovery projects across the country.

India's biotechnology industry holds the potential for boundless growth. Global biotech companies will continue investing in India as long as India continues investing in biotechnology. BIO stands ready and committed to working with biotechnology leaders in India to deliver on the enormous promise and potential of their biotech sector.

Of note, BIO India will be held Sept. 21–22 in Hyderabad.

Alan Eisenberg is the executive vice-president of Emerging Companies and Business Development for the Biotechnology Industry Organization (BIO).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here